Lei Zhou, Hui Li, Anxiu Sun
Department of Pharmacy, Taixing People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China.
Department of Medicine, Taixing People Hospital, Taizhou, Jiangsu, China.
Iran J Public Health. 2025 Jul;54(7):1493-1503. doi: 10.18502/ijph.v54i7.19156.
Drug use disorders (DUDs) pose a serious public health threat, exacerbating the worldwide disease burden and resulting in a dramatic rise in fatalities. We aimed to explore the global and cross-country disparities in the fatal and non-fatal burden attributable to DUDs and subtypes by sex and age groups from 1990 to 2021.
The Global Burden of Disease (GBD) 2021 data were analyzed to estimate the fatal [i.e. mortality and years of life lost (YLL)], non-fatal [i.e. disability-adjusted life years (DALYs), years lived with disability (YLD)] burden, trend attributable to DUDs, subtypes by sex and age groups using the joinpoint regression model across India, China, as well as world between 1990 and 2021.
Between 1990 and 2021, the age-standardized fatal and non-fatal rates attributable to DUDs significantly increased in India and the world, whereas substantially declined in China. China experienced a 2-fold higher age-standardized DALYs and YLDs rate in 2021, and India observed the fastest (2-fold) upward trend in the age-standardized mortality and YLLs rate attributable to amphetamine use disorders than the world. The trend in YLD rate attributable to DUDs significantly increased in the young age group <20 years in India. The world experienced a significant increasing trend in the fatal rate attributable to DUDs in the middle age group 20-54 years. Overall, females observed remarkable improvement in the fatal and non-fatal burden attributable to DUDs across India, China and the world.
India and the global population experienced rising age-standardized fatal and non-fatal rates due to DUDs-while China demonstrated progress. The trend varied by DUD subtypes, age group, and gender, with amphetamine use disorders disproportionately affecting India and China and females showing improved outcomes across all regions.
药物使用障碍对公众健康构成严重威胁,加剧了全球疾病负担并导致死亡人数急剧上升。我们旨在探讨1990年至2021年期间,按性别和年龄组划分,药物使用障碍及其亚型所致的致命和非致命负担在全球及各国之间的差异。
分析《2021年全球疾病负担》数据,以估计印度、中国以及1990年至2021年期间全球范围内,药物使用障碍及其亚型按性别和年龄组划分所致的致命负担(即死亡率和生命损失年数)、非致命负担(即伤残调整生命年、带病生存年数),采用连接点回归模型分析趋势。
1990年至2021年期间,印度和全球范围内,药物使用障碍所致的年龄标准化致命和非致命率显著上升,而中国则大幅下降。2021年,中国的年龄标准化伤残调整生命年和带病生存年数率高出两倍,印度在苯丙胺使用障碍所致的年龄标准化死亡率和生命损失年数率方面的上升趋势(两倍)比全球更快。印度20岁以下的年轻年龄组中,药物使用障碍所致的带病生存年数率趋势显著上升。全球20至54岁的中年年龄组中,药物使用障碍所致的致命率呈现显著上升趋势。总体而言,印度、中国和全球范围内,女性在药物使用障碍所致的致命和非致命负担方面均有显著改善。
印度和全球人口因药物使用障碍导致年龄标准化致命和非致命率上升,而中国则取得了进展。趋势因药物使用障碍亚型、年龄组和性别而异,苯丙胺使用障碍对印度和中国的影响尤为严重,而所有地区的女性情况均有所改善。